Structured penalized regression for drug sensitivity prediction by Zhao, Zhi & Zucknick, Manuela
STRUCTURED PENALIZED REGRESSION
FOR DRUG SENSITIVITY PREDICTION
By Zhi Zhao and Manuela Zucknick
Department of Biostatistics, University of Oslo
P.O.Box 1122 Blindern 0317 Oslo, Norway
Large-scale in vitro drug sensitivity screens are an important tool
in personalized oncology to predict the the effectiveness of potential
cancer drugs. The prediction of the sensitivity of cancer cell lines
to a panel of drugs is a multivariate regression problem with high-
dimensional heterogeneous multi-omics data as input data and with
potentially strong correlations between the outcome variables which
represent the sensitivity to the different drugs. We propose a joint
penalized regression approach with structured penalty terms which
allow us to utilize the correlation structure between drugs with group-
lasso-type penalties and at the same time address the heterogene-
ity between omics data sources by introducing data-source-specific
penalty factors to penalize different data sources differently. By com-
bining integrative penalty factors (IPF) with tree-guided group lasso,
we create the IPF-tree-lasso method. We present a unified framework
to transform more general IPF-type methods to the original penalized
method. Because the structured penalty terms have multiple param-
eters, we demonstrate how the interval-search Efficient Parameter
Selection via Global Optimization (EPSGO) algorithm can be used
to optimize multiple penalty parameters efficiently. Simulation stud-
ies show that IPF-tree-lasso can improve the prediction performance
significantly. Finally, we employ the new methods to analyse data
from the Genomics of Drug Sensitivity in Cancer project.
1. Introduction. With the advancements of high-throughput sequencing technolo-
gies, pharmacogenomics has been provided an emerging strategy for identifying personal-
ized therapies from a mount of discovery drug candidates by using multi-omics data to
characterize the whole biological system Hatzis et al. (2014); Bredel and Jacoby (2004). In
personalised oncology in particular, large-scale in-vitro drug screens can be used to pre-
dict which drugs or drug combination will be effective for a patient given the particular
molecular profile of the patient’s tumour.
In early publications (Barretina et al., 2012; Garnett et al., 2012), penalized linear regres-
sion methods, in particular the elastic net (Zou and Hastie, 2005), were used to demonstrate
the potential of molecular data to predict the sensitivity of cancer cell lines to drugs. How-
ever, these papers only considered separate univariate models for each drug, and could thus
not take the strong correlation structure between drugs due to similarities in drug function
Ferdousi, Safdari and Omidi (2017) into account. They also did not address heterogeneity
between the different molecular data sources, for example expected differences in sparsity
levels in the associations with the response variables Hasin, Seldin and Lusin (2017). In
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2this work, we therefore propose and investigate a range of structured penalty terms in a
multivariate linear regression setup, that allow us to take the known structure in the drug
screen data better into account.
In recent years, several groups and consortia have developed big datasets which include
large-scale ex vivo pharmacological profiling of cancer drugs on panels of cancer cell lines
and the genomic profiling of these cancer cell lines (Barretina et al., 2012; Daemen et al.,
2013; Garnett et al., 2012; Greshock et al., 2010; Haverty et al., 2016). The genomic data
can for example consist of genome-wide measurements of mRNA expression, DNA copy
numbers, DNA single-point and other mutations or CpG methylation of the cell lines taken
at baseline, i.e. before treatment. They reflect different heterogeneous molecular profiles of
the cancer cell lines with respect to effect sizes as level of sparsity in the effects (i.e. number
of non-zero effects), correlations and collinearity, measurement scales and background noise
(Hasin, Seldin and Lusin, 2017). The drug sensitivity profiles for some groups of drugs are
expected to be correlated, due to their common targets and similar pharmacodynamic
behaviours.
To analyze such data, one straightforward method is to use (penalized) linear regression
methods, regressing each drug on all molecular features in a linear manner, for example
lasso (Tibshirani, 1996) or the elastic net. Both methods can select a few relevant features
with nonzero regression coefficient estimates from a large number of features. But they
cannot address the heterogeneity of different molecular data sources. Boulesteix et al. (2017)
introduced integrative `1-penalized regression with penalty factors (IPF-lasso) to shrink
the effects of features from different data sources with varying `1-penalties, to reflect their
different relative contributions. While lasso or IPF-lasso can be extended to multivariate
regression to jointly model multiple drugs sensitivity, the correlation of drugs is not reflected
in the penalization of regression coefficients. Kim and Xing (2012) proposed tree-guided
group lasso (tree-lasso) to estimate structured sparsity of multiple response variables by
assuming a hierarchical cluster structure in the response variables. Each cluster is likely to
be influenced by some common features, for which the effects are similar between correlated
responses.
In this article, we propose the IPF-tree-lasso which borrows the strength of varying
penalty parameters from IPF-lasso and the cluster structure in multivariate regression from
tree-lasso. Thus, IPF-tree-lasso can capture the different relative contributions of multiple
omics input data sources and the group structure of correlated drug response variables.
Since some cancer drugs might have similar mechanisms, for example the same target gene
or signaling pathway, these drugs are likely to have correlated sensitivities. IPF-tree-lasso
will select common relevant molecular features of these correlated drugs, and accordingly
achieve similar regression coefficient estimates via a group-lasso-type penality.
Elastic net (Zou and Hastie, 2005) is also compared here, because it considers the group-
ing effect of correlated features and the `2-penalty can improve the prediction performance
over lasso. Additionally, we also formulate the integrative elastic net with penalty fac-
tors (IPF-elastic-net) model to provide a flexible extension of the elastic net with varying
complexity parameters λ’s as well as varying parameters α’s.
However, IPF-tree-lasso and IPF-elastic-net have more complicated penalty terms which
might require new optimization algorithms. We use an augmented data matrix formulation,
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so that the original cyclical coordinate descent algorithm for lasso (Friedman, Hastie and
Tibshirani, 2010) and smoothing proximal gradient descent method proposed for tree-lasso
(Kim and Xing, 2012) can be employed directly. As elastic net and IPF-type methods have
multiple penalty parameters to be optimized, a standard grid search is computationally not
efficient (Jones, Schonlau and Welch, 1998). Instead, we modify and employ the interval-
search algorithm Efficient Parameter Selection via Global Optimization (EPSGO) proposed
by Frohlich and Zell (2005). Sill et al. (2014) implemented the EPSGO algorithm for elastic
net models in the R package c060. We have adapted the c060 package for efficient penalty
parameters optimization for IPF-tree-lasso and IPF-elastic-net.
The introduction of structured penalty terms that are tailored to the specific structure
of large-scale in vitro drug sensitivity screening experiments can improve prediction per-
formance, especially for groups of drugs that have the same mechanism of action and are
therefore quite similar in their drug sensitivity profiles. But maybe even more importantly,
the structured penalties also improve interpretation of the results, for example by high-
lighting to which groups of drugs (rather than only individual drugs) certain cell lines tend
to show high drug sensitivity, or by allowing a comparison of the relative importance of
the different omics data sources through their penalty factor ratios. In general, the joint
analysis of all drugs and all cell lines from a drug sensitivity screen within a multivariate
regression framework makes it easier to understand commonalities as well as differences
in the drug sensitivity profiles, e.g. to understand which cell lines and tissue types show
similar behaviour within groups of drugs with similar modes of action. Note that we ex-
tended all the methods discussed in this manuscript to allow the inclusion of un-penalised
mandatory co-variates, in particular cancer tissue type.
The rest of the paper is organized as follows. In Section 2, we introduce the data setup and
outline the consequences that this has for the construction of the structured penalty terms.
We further briefly introduce all methods considered in the simulation studies and data ap-
plication, from standard penalized regression methods to their newly developed extensions
with structured penalty terms. The performance of the various methods is compared and
evaluated in a simulation study described in Section 3, where the data are simulated to
mimic typical large-scale drug screen scenarios. We finally perform a detailed analysis of
data from the Genomics of Drug Sensitivity in Cancer project (Garnett et al., 2012) in
Section 4, which includes a discussion of some highlights of the biological implications.
Lastly, we discuss the main findings and conclude the paper in Section 5.
2. Structured penalties for multivariate regression. The pharmacological data
are collected for n samples (e.g., cell lines or patients) and m response variables (typically
drug sensitivity). The response variables are denoted by Y = {yik} (i ∈ [n] ≡ {1, · · · , n},
k ∈ [m]), where yik means the response of the ith cell line treated with the kth drug
as illustration in Figure 1. The high-dimensional (i.e., multi-omics) data including S data
sources contain p =
∑S
s=1 ps features in total, and all p features are available for all samples,
denoted by [X1, · · · ,XS ] = X = {xij} (i ∈ [n], j ∈ [p]). The linear model mapping from
high-dimensional data to multivariate responses is
(2.1) Y = 1nβ
>
0 +XB+E,
4Fig 1: Illustration of the response data and multiple data sources. The Y is measured
from n cell lines and m drugs. For each cell line, gene expression (GEX) X1, copy number
variation (CNV) X2, · · · and mutation (MUT) XS are obtained which have p1, p2, · · · and
pS features, respectively.
where 1n = (1, · · · , 1)> is an n-column vector, β0 = (β01, · · · , β0m)> is the intercept vector
corresponding to m response variables, B is a p×m regression coefficients matrix, and E
is a n ×m noise matrix. (β0,B) can be estimated by minimizing the sum of the residual
sum of squares and a penalty function as following
(2.2) min
β0,B
{
1
2mn
‖Y − 1nβ>0 −XB‖2F + pen(B)
}
,
where ‖· ‖F is the Frobenius norm.
2.1. Lasso and elastic net. When p is very large, especially n  p, and pressuming
only a few true relevant features, the `1-penalized regression, or lasso (Tibshirani, 1996)
is a standard method to identify those features by their nonzero coefficient estimates. The
multivariate lasso uses the `1-norm penalty function pen(B) = λ‖B‖`1 in (2.2), where
‖B‖`q = (
∑
j,k |βjk|q)1/q (q ∈ [1,∞)) and λ > 0 is the given penalty parameter that
controls the strength of penalizing coefficients.
Another regularization method is elastic net (Zou and Hastie, 2005), which takes a bias-
variance trade-off between lasso and the continuous shrinkage method ridge regression. The
ridge penalty (`2-penalty) tends to include or exclude strongly correlated features together.
The penalty function of elastic net in (2.2) is pen(B) = λ(α‖B‖`1 + 12(1−α)‖B‖2`2), where
α ∈ [0, 1] gives the compromise between ridge (α = 0) and lasso (α = 1).
2.2. IPF-lasso and IPF-elastic-net. Lasso and elastic net penalize all coefficients of
features by globally controlling penalty parameters λ and α. In order to distinguish the
contributions of heterogeneous data sources, Boulesteix et al. (2017) proposed IPF-lasso
to analyze multi-omics data. IPF-lasso allows varying penalty parameters to weight the
norms of different sources’ coefficients. For multivariate responses, the penalty function is
pen(B) =
∑
s λs‖Bs‖`1 (s ∈ [S]), where λs > 0, B = [B1..
. · · · ...BS ] stacks Bs by rows and
Bs is the coefficients matrix corresponding to the sth data source. After transforming the
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Fig 2: Prediction performance of IPF-lasso for (n,m, p1, p2) = (100, 24, 500, 150) with dif-
ferent penalty parameter ratios λ2/λ1. It is exactly lasso when λ2/λ1 = 1. The details of
the simulated data are as scenario 2 in Section 3.1.
X matrix as follows:
X? =
[
X1,
λ1
λ2
X2, · · · , λ1λSXS
]
∈ Rn×(p1+···+pS),
B? =
[
B1.
..λ2
λ1
B2.
.. · · · ...λSλ1BS
]
∈ R(p1+···+pS)×m,
then Bˆ? =
[
Bˆ1.
..λ2
λ1
Bˆ2.
.. · · · ...λSλ1 BˆS
]
where Bˆ = [Bˆ1.
..Bˆ2.
.. · · · ...BˆS ].
When there are two data sources, i.e., S = 2, Figure 2 shows that the prediction perfor-
mance as mean squared error of cross validation, i.e., MSECV, is convex in versus λ1 when
fixing the two penalty parameters ratio λ2/λ1.
A simple integrative `1/`2-penalty method with penalty factors (sIPF-elastic-net) has
pen(B) =
∑
s λs(α‖Bs‖`1 + 12(1 − α)‖Bs‖2`2) where λs > 0 (s ∈ [S]) and α ∈ [0, 1]. Here,
different data sources share the same parameter α, which forces the same strength to shrink
the coefficients of strongly correlated features towards each other. That is similar grouping
effect as elastic net (see Supplementary S1 for more details). The fully flexible version of
the IPF-elastic-net has penalty function
(2.3) pen(B) =
∑
s
λs(αs‖Bs‖`1 +
1
2
(1− αs)‖Bs‖2`2),
6where λs > 0, αs ∈ [0, 1] (s ∈ [S]). By defining the transformation
X? =

1
α1
X1
λ1
α2λ2
X2 . . .
λ1
αSλS
XS
1
α1
√
1
2λ1(1− α1)Ip1 0 . . . 0
0 λ1α2λ2
√
1
2λ2(1− α2)Ip2 . . . 0
...
...
. . .
...
0 0 . . . λ1αSλS
√
1
2λS(1− αS)IpS

∈ R(n+p)×p,
Y? = [Y
...0
... · · · ...0] ∈ R(n+p)×m,
B? =
[
α1B1.
..α2λ2
λ1
B2.
.. · · · ...αSλSλ1 BS
]
∈ Rp×m,
λ?1 = λ1/{2m(n+
∑
s
ps)},
αs ∈ (0, 1], s ∈ 1, · · · , S,
then it becomes a lasso problem
(βˆ0, Bˆ
?) = arg min
β0,B?
{
1
2mn
‖Y? − 1n+pβ>0 −X?B?‖2F + λ?1‖B?‖`1
}
.
2.3. Tree-lasso and IPF-tree-lasso. Kim and Xing (2012) proposed the tree-lasso method
which uses a hierarchical tree structure over the response variables in a group-lasso based
penalty function. As illustrated in Figure 3 we hypothesize that highly correlated response
variables in each cluster are likely to be influenced by a common set of features. The hier-
archical tree structure of multiple response variables can be represented as a tree T with
a set of vertices V and groups {Gν : ν ∈ V }. It can be given by prior knowledge of the
pharmacokinetic properties of the drugs, or be learned from the data, for example by hier-
archical clustering. Given the tree T and groups Gν , the penalty function of the tree-lasso
is defined as
pen(B) = λ
p∑
j=1
∑
ν∈V
ων‖βGνj ‖`2
= λ
p∑
j=1
∑
ν∈Vleaf
‖βGνj ‖`2 + λ
p∑
j=1
∑
ν∈Vint
ων‖βGνj ‖`2
= λ
p∑
j=1
∑
ν∈Vleaf
|βGνj |+ λ
p∑
j=1
∑
ν∈Vint
{hν ·
∑
c∈Children(ν)
ωc‖βGcj ‖`2 + (1− hν)‖βGνj ‖`2},
where βGνj = {βjk : k ∈ Gν} is the jth row of B associated with response variables in
group ν, ων is either the weight associated with the height hν of each internal node in
tree T or ων = 1 for the leaf node, Vint and Vleaf are the internal nodes and leaves of the
tree, respectively. For example, consider a case with two drugs and a tree of three nodes
that consists of two leaf nodes and one root node. It is illustrated as the following subtree
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Fig 3: An illustration of a tree lasso with three drugs (figure courtesy of Kim and Xing
(2012)). (a): The sparse coefficients matrix is shown with white blocks for zeros and grey
blocks for nonzero values. The hierarchical clustering tree above represents the correlation
structure in drugs. The first two drugs corresponding to the first two columns are highly
correlated and have two common influence covariates (1st and 6th rows). (b): Groups of
coefficients associated with each node of the tree in panel (a) in the tree-lasso penalty.
βjk(j ∈ [8], k ∈ [3]) denotes the coefficient of the kth drug’s jth variable.
of tree T in Figure 3, V = {ν1, ν2, ν4}, βGν1j = {βj1 : j ∈ [p]}, β
Gν2
j = {βj2 : j ∈ [p]},
β
Gν4
j = {βjk : j ∈ [p]; k ∈ {1, 2}}. Then the penalty function for this tree is
(2.4)
pen(B) = λ
p∑
j=1
{ |βj1|︸︷︷︸
leaf Gν1
+ |βj2|︸︷︷︸
leaf Gν2
+hν4( |βj1|︸︷︷︸
leaf Gν1
+ |βj2|︸︷︷︸
leaf Gν2
) + (1− hν4)
√
(βj1)2 + (βj2)2︸ ︷︷ ︸
internal Gν4
}.
We can now define IPF-tree-lasso, where different λ’s are employed for different data
sources. Its penalty function is defined as follows
(2.5) pen(B) =
S∑
s=1
λs
 ps∑
j=1
∑
ν∈Vint
ων‖βGνj,s ‖`2 +
ps∑
j=1
∑
ν∈Vleaf
‖βGνj,s ‖`2
 ,
where βj,s is the jth row of coefficients corresponding to sth data source. The same trans-
formation as IPF-lasso also makes IPF-tree-lasso to the equivalent tree-lasso problem (see
Supplementary S2 for more details).
Proposition 1. Generally, the penalized objective function can be formulated as
(2.6) min
β0,B
 12mn‖Y − 1nβ>0 −XB‖2F + λ
p∑
j=1
∑
g∈G
wg‖Sgj (B)‖`qj,g
 ,
where Sgj (B) is the a submatrix of B, qj,g ∈ [1,∞], λ is a tuning parameter, G contains pre-
defined groups and all group weights wg’s are known or can be pre-estimated. The submatrix
Sgj (B) = {βjk : j ∈ Mg, k ∈ Ng} is associated with specified set of rows Mg ⊆ [p] and
8columns Ng ⊆ [m]. Let X = [X1, . . . ,XS ] with numbers of features p1, . . . , pS, respectively,
p =
∑S
s=1 ps and B = [B1.
.. · · · ...BS ]. The corresponding IPF problem
(2.7) min
β0,B
 12mn ||Y − 1nβ>0 −XB||2F +
S∑
s=1
ps∑
j=1
∑
g∈G
λswg‖Sgj (Bs)‖`qj,g

can be transformed into the equivalent original problem
min
β0,B?
 12mn‖Y − 1nβ>0 −X?B?‖2F + λ1
p∑
j=1
∑
g∈G
wg‖Sgj (B?)‖`qj,g
 ,
where X? = [X1,
λ1
λ2
X2, · · · , λ1λSXS ], B? = [B1..
.λ2
λ1
B2.
.. · · · ...λSλ1BS ] and S
g
j (B
?) = {β?jk : j ∈
Mg, k ∈ Ng}, if
⋃
Mg = [p] and
⋃
Ng = [m]. If
⋃
Mg $ [p] and (or)
⋃
N $ [m], then the
elements {β?jk : j ∈ [p]\
⋃
Mg, k ∈ [m]\
⋃
Ng} and the non-penalized features are remained
in the Frobenius-norm loss function. The rows in Mg and the columns in Ng need not be
contiguous, and Sgj (Bs) can be overlaping.
The Proposition 1 allows different norms for different submatrices in the penalty term.
IPF-lasso and IPF-tree-lasso are special cases of (2.7), that is,
• IPF-lasso: G = {1}, wg = 1, Sgj (Bs) = Bs, `qj,g = `1;
• IPF-tree-lasso: G = {Vleaf, Vint}, Sgj (Bs) = βGvj , `qj,g = `2.
In (2.6), ‖Sgj (B)‖`∞ = sup{|βjk| : j ∈ Mg, k ∈ Ng} is likely to seek a common subset of a
submatrix Sg(B), in which selected features will be relevant to multiple response variables
simultaneously (Turlach and others, 2005). Since the penalty term in (2.7) allows the
overlaps of submatrices, it can contain more integrated penalty cases. For example, sparse-
group lasso (Simon et al., 2012) with `1 and `2 penalties actually allows the overlaps
of coefficient groups (including singletons). Jacob, Obosinski and Vert (2009) proposed
group lasso allowing overlaps in combination with graphical lasso. Li, Nan and Zhu (2015)
proposed the multivariate sparse group lasso, where an arbitrary group structure such as
overlapping or nested or multilevel hierarchical structure is considered. All these methods
can be extended into corresponding IPF-type methods and be solved by Proposition 1.
However, (2.7) does not include graphical lasso or fused lasso. If there is a non-identity
transformation of the submatrix of B inside of the norm in the penalty term, the augmented
matrix will be complicated. It also cannot be applied to the IPF-elastic-net because of the
‖ · ‖2`2 penalty (2.3), unless
λ21(1−αs)2
2λsα2s
is a constant.
2.4. Implementation. For the implementation, we give an initial decreasing λ sequence,
starting at λmax which shrinks all coefficients to zero (Friedman, Hastie and Tibshirani,
2010), for lasso, elastic net, IPF-lasso and sIPF-elastic-net. The multivariate responses Y
are vectorized to vec(Y). The interval-search algorithm Efficient Parameter Selection via
Global Optimization (EPSGO) is applied to find the optimal α in elastic net type methods
(Frohlich and Zell, 2005; Sill et al., 2014), as well as penalty parameters ratios in IPF-type
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methods. The EPSGO algorithm updates the tuning parameters through learning a Gaus-
sian process model of the loss function surface from the points which have already been
visited. Note that parameter tuning for IPF-elastic-net with varying α’s remains challeng-
ing even when using the EPSGO algorithm due to the large number of parameters in a
non-convex situation. For IPF-tree-lasso, λ1 is optimized by exploring a given sequence of
values, while the EPSGO algorithm is used to determine the optimal penalty parameters
ratios λs/λ1 (s > 1). The IPF-tree-lasso is implemented based on the equivalent tree-lasso
problem, which is more efficient than directly adapting the original tree-lasso algorithm
to iterate coefficients of different data sources respectively (see Supplementary S3). The
tree structure is pre-estimated from the response data by hierarchical agglomerative clus-
tering (Golub et al., 1999) and only using the nodes with normalized heights larger than
a pre-determined threshold ρ? to ignore groups with weak correlations between response
variables. Optimal penalty parameters are found by minimizing the MSECV as loss func-
tion on the learning data, and independent validation data are used to obtain prediction
mean squared errors (MSEval) to evaluate prediction performance.
3. Simulations.
3.1. Simulation scenario. We simulate data to demonstrate the prediction performance
and variable selection performance of lasso, elastic net, tree-lasso and their corresponding
IPF-type methods. We assume n = 100 samples, multiple responses with m = 24 drugs
Y, and two data sources of p1 gene expression features X1 and p2 mutation features X2
(p1 > n, p2 > n). The drug sensitivity responses are simulated according to the linear
model
(3.1) Y = [X1,X2]
[
B1
B2
]
+E.
To simulate the molecular data matrix X = [X1,X2], we first sample from a multivariate
normal distribution with mean 0 and a nondiagonal (p1 +p2)× (p1 +p2) covariance matrix
Σ as Boulesteix et al. (2017) suggested, i.e., X˜ = [X1, X˜2] ∼ N (0, Σ⊗ In), where
Σ =

Ap1/b(σ) . . . 0 Bp1/b,p2/b(σ) . . . 0
...
. . .
...
...
. . .
...
0 . . . Ap1/b(σ) 0 . . . Bp1/b,p2/b(σ)
Bp2/b,p1/b(σ) . . . 0 Ap2/b(σ) . . . 0
...
. . .
...
...
. . .
...
0 . . . Bp2/b,p1/b(σ) 0 . . . Ap2/b(σ)

.
Further dichotomizing X2 = 1{X˜2>0} where 1{·} is an indicator function and let X =
[X1,X2]. The second data source is dichotomized to simulate the common situation that
one data source represents binary gene mutations. In the covariance matrix Σ, blocks
Ap1/b(σ) and Ap2/b(σ) capture the covariances of features among the first and second data
source, respectively. In each data source, there are b latent groups of size (p1/b) × (p1/b)
and (p2/b) × (p2/b), respectively, represented by blocks Bp1/b,p2/b and Bp2/b,p1/b in which
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any two features have covariance σ. We set σ = 0.4, b = 10, and the variance of each feature
is one. Considering that different data sources might have different numbers of features, we
simulate two cases, (p1, p2) = (150, 150) and (p1, p2) = (500, 150). In (3.1), the noise term
E = {ik} (i ∈ [n]; k ∈ [m]), and {ik} iid∼ N (0, 1).
We assume that multiple responses can be grouped and the group relationships can be
addressed by a hierarchical tree structure. In our intended applications, different molecular
information may explain different group effects in the drug response variables. In the first
simulation scenario, we design two different hierarchical tree effects from the two data
sources, as illustrated in Figure 4(a). The groups in the first 12 response variables are
determined by the first data source, and the second data source determines the groups in
the second 12 responses. The two hierarchical structures are generated by the two matrices
B1 and B2 illustrated in Figure 4(a). In a second simulation scenario the two data sources
do not determine the drug groups separately, but instead in an overlapping manner. For
this we design two very different hierarchical structures with B1 and B2, as illustrated in
Figure 4(b). In scenario 3, to test the sensitivity to model misspecification, we set a control
case which has no tree-structured B1 and B2 as shown in Figure 4(c). The patterns of B1
and B2 in Figure 4(c) correspond to the designed “hotspots” referring to the simulation
by Lewin et al. (2016).
To evaluate the prediction performance of different methods, we calculate MSEval from
the simulated validation data Xval and Yval which are simulated independently in an iden-
tical manner to X and Y. Additionally, we compare the accuracy of variable selection
performance, where we use the terms sensitivity to denote the percentage of nonzero coef-
ficients accurately estimated as nonzeros and specificity to denote the percentage of zero
coefficients accurately estimated as zeros. Algorithm 1 in Supplementary S5 summarizes
the procedure of the simulation study.
3.2. Simulation results and discussion. We run 50 simulations and show in Figure 5
the prediction performance of all methods in the different scenarios. When the two data
sources have the same number of features (i.e., p1 = p2 = 150) and similar trees for B1 and
B2 as in scenario 1 (Figure 4(a)), then lasso, IPF-lasso, elastic net and sIPF-elastic-net
have similar prediction performance in terms of MSEval (Figure 5(a)). But tree-lasso and
IPF-tree-lasso outperform other methods. However, when the two data sources are more
different as in design scenario 2 (Figure 4(b)), IPF-lasso and sIPF-elastic-net are slightly
superior to lasso and elastic net in the situation of p1 = p2 = 150 (Figure 5(c)). IPF-
tree-lasso further improves the prediction. In the control case, Figure 5(e) (scenario 3),
tree-lasso and IPF-tree-lasso still have better prediction.
When the two data sources have different feature numbers (i.e., p1 = 500, p2 = 150),
IPF-type methods (IPF-lasso, sIPF-elastic-net and IPF-tree-lasso) have lower MSEval than
their corresponding non-IPF-type methods (lasso, elastic net and tree-lasso) respectively in
all three scenarios (Figure 5(b), (d) and (f)). When comparing scenario 2 with scenario 1 in
the case (p1, p2) = (500, 150), IPF-type methods improve the prediction more significantly
in scenario 2.
Table 1 displays the accuracy of coefficients matrix estimation and variable selection for
scenario 1. According to the averaged absolute errors of estimated coefficients, 1mp‖Bˆ−B‖`1 ,
all methods performe similarly if (p1, p2) = (150, 150) but the IPF-type methods perform
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Fig 4: Three simulation scenarios: structured B1 and B2 corresponding to hierarchical trees
to generate hierarchically structured Y for scenarios (a) and (b). Black blocks indicate
coefficient values of 0.6, grey blocks 0.2 and white blocks 0. The three scenarios have are
432, 720 and 216 nonzero coefficients, respectively. The two dendrograms on left of B in
panel (a) or (b) show the hierarchical relationships of multivariate responses generated by
B1 and B2, respectively.
Fig 5: Comparison of MSEval between different approaches in the three simulation scenarios
with 50 simulations. The three panels of top are based on the same feature number of X1
and X2, p1 = p2 = 150. The three panels of bottom are based on p1 = 500 features of X1
and p2 = 150 features of X2.
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Table 1
Accuracy of coefficients recovery by simulated hierarchical structured Y as scenario 1
1
mp
‖Bˆ−B‖`1 sensitivity specificity V S
Model p1 = 150, p2 = 150
Lasso 0.021 0.835 0.904 1008
IPF-lasso 0.021 0.789 0.912 940
Elastic-net 0.022 0.850 0.891 1103
sIPF-elastic-net 0.022 0.806 0.901 1016
Tree-lasso 0.022 0.926 0.671 2627
IPF-tree-lasso 0.022 0.917 0.680 2564
p1 = 500, p2 = 150
Lasso 0.022 0.823 0.943 1219
IPF-lasso 0.021 0.758 0.959 950
Elastic-net 0.023 0.838 0.936 1329
sIPF-elastic-net 0.021 0.769 0.955 1011
Tree-lasso 0.024 0.918 0.755 4121
IPF-tree-lasso 0.022 0.903 0.790 3569
All results are the average of 50 simulations. Sensitivity denotes the percentage
of nonzero coefficients estimated as nonzeros and specificity to denote the
percentage of zero coefficients estimated as zeros. The variable selection index
V S =
∑p
j=1
∑m
k=1 1{βˆ(r)
jk
6=0} indicates the number of selected features.
slightly better for (p1, p2) = (500, 150). In both cases, (p1, p2) = (150, 150) and (p1, p2) =
(500, 150), IPF-lasso, sIPF-elastic-net, and IPF-tree-lasso select fewer features and achieve
larger specificity than non-IPF-type methods, but they lose sensitivity.
In the simulations, we mainly focus on simulating hierarchically structured drug sensitiv-
ity according to the specifically designed coefficient matrices as in Figure 4(a) (scenario 1)
and Figure 4(b) (scenario 2). In both scenarios 1 and 2, the tree-lasso model improves per-
formance. But even in the case of non-structured Y (scenario 3) tree-lasso still outperforms
lasso and elastic net in Figure 5(e), because some of the correlation structures among re-
sponse variables can be captured by a tree structure. For example, the nonzero blocks in B
in Figure 4(c) illustrate different response variables that are likely to be similar since these
responses can be explained by the same features. Kim and Xing (2012) also showed that
tree-lasso can take into account such correlations even when the tree structure is not fully
realized. Compared to the top three panels of Figure 5, the bottom three panels reflect a
greater contribution to prediction performance of IPF-type methods. In all situations, IPF-
tree-lasso achieves the best prediction, at least as good as tree-lasso when p1 = p2 = 150,
and the IPF-lasso and sIPF-elastic perform quite well when (p1, p2) = (500, 150). It is be-
cause that IPF-tree-lasso does not only consider the correlations among responses, but also
distinguishes the relative contributions of two data sources with varying penalty parameters
λ1 and λ2.
4. Genomics of Drug Sensitivity in Cancer data analysis. The Genomics of
Drug Sensitivity in Cancer (GDSC) database (Yang et al., 2013) was developed from
a large-scale pharmacogenomic study, where a range of potential anticancer therapeutic
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compounds was tests on several hundred cancer cell lines. The drug sensitivity of a cell
line, measured as half-maximal inhibitory concentration (IC50), was estimated by fitting
a Bayesian sigmoid model to dose-response curves obtained for a range of drug concen-
trations corresponding to the 72 hours’ effect of drug treatment on cell viability, see Gar-
nett et al. (2012) for the modelling details. We use the data from their archived files
(ftp://ftp.sanger.ac.uk/pub4/cancerrxgene/releases/release-5.0/), where there
are 97 cancer drugs tested on 498 cancer cell lines with complete availability of IC50
measurements after excluding one cell line with one unrealistically small estimate for
IC50 = 1.43 × 10−16µM . The cell lines represent tumor samples from 13 different tis-
sue types. Cell lines are characterized by the following genomic data which are available
as baseline measurements: genome-wide measurement of mRNA expression, copy numbers
and DNA single point and other mutations. We preselect 2602 gene expression features
with the largest variances over cell lines, which in total explain 50% of the variation.
In addition, we use copy number variation data for 426 genes and mutation data for
68 genes which are causally implicated in cancer according to the Cancer Gene Census
(https://cancer.sanger.ac.uk/census).
We randomly select 80% cell lines of each cancer tissue type for training data and the
other 20% as validation data. A multivariate regression model is fitted to the 80% training
data:
(4.1) Y = 1nβ
>
0 +X0B0 +XB+E,
where Y is the log IC50, β0 is the intercept vector, X0 represents the cancer tissue types
by dummy variables, and X = [X1,X2,X3] consists of the log-transformed gene expression
variables (X1), the counting copy number variables (X2) and binary mutation variables
(X3). Let B = [B1.
..B2.
..B3] correspond to the coefficient matrices of the three data sources.
Since tissue types are known to have large effects on drug sensitivity and X0 is low-
dimensional, we do not penalize the coefficients B0 of cancer tissue types when fitting
the model (4.1). Supplementary S6 outlines the estimation of non-penalized coefficients in
the tree-lasso model. The 20% validation data are used to evaluate prediction performance
by MSEval. The implementation procedure of (4.1) by all methods is the same as the
simulation studies (Algorithm 1 of Supplementary S5). Additionally, R2val is computed as
R2val ≡ 1−
SSEval
SSTval
= 1− ‖Yval − 1nβˆ
>
0 −XvalBˆ‖2F
‖Yval − 1nY¯val‖2F
,
where Xval and Yval are the 20% validation data, Y¯val is a column vector with averaged
log IC50 of each drug over the validation data samples. For comparison we also fit two
low-dimensional linear regression models: (i) the “NULL” model which only includes an
intercept vector, and (ii) the “OLS” model which includes the intercept vector and dummy
variables X0 representing the cancer tissue types.
To eliminate the uncertainty of splitting the data randomly into training|validation sets,
Table 2 reports the averaged results of 10 different random splits of the GDSC data. When
only using the 13 tissue categories as predictors (“OLS” model), the prediction performance
is very poor, MSEval=3.199 and R
2
val = 0.036 averaged over the 10 repetitions. However,
including the genomic information improves the prediction in the lasso and elastic net
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Table 2
Prediction and the numbers of selected features in the GDSC data analysis
Method NULL Lasso elastic net Tree-lasso
V S? - 302+1+92 315+1+93 21928+8149+1
1
mpV S
? - 0.1% 0.1% 10.0%
MSECV (s.e.) 3.360(0.027) 3.200 (0.040) 3.198 (0.039) 3.138 (0.040)
MSEval (s.e.) 3.368 (0.107) 3.151 (0.077) 3.149 (0.077) 3.069 (0.079)
R2val (s.e.) -0.014 (0.008) 0.051 (0.012) 0.052 (0.014) 0.076 (0.019)
OLS IPF-lasso sIPF-elastic-net IPF-tree-lasso
V S? - 774+11+74 252394+41322+6596 30567+515+452
1
mpV S
? - 0.3% 100.0% 10.5%
MSECV (s.e.) 3.013 (0.016) 3.182 (0.037) 3.179 (0.036) 3.068 (0.035)
MSEval (s.e.) 3.199 (0.074) 3.134 (0.078) 3.130 (0.076) 3.025 (0.074)
R2val (s.e.) 0.036 (0.016) 0.056 (0.014) 0.057 (0.015) 0.089 (0.018)
The variable selection index V S? =
∑p
j=1
∑m
k=1
{(∑10
r=1 1{βˆ(r)jk 6=0}
)
≥ 2
}
indicates
the features selected at least twice over the 10 repetitions. 1mpV S
? is the proportion
of the number of selected features. The NULL model is Y = 1nβ
>
0 + E. The OLS
model only includes the 13 cancer tissue types information as predictors, i.e., Y =
1nβ
>
0 +X0B0+E where (βˆ0, Bˆ0) are OLS estimates. The number of estimated nonzero
coefficients, #{βˆjk 6= 0 : j ∈ [p], k ∈ [m]}, corresponds to the mRNA expression, copy
numbers and mutation, which are selected at least twice in the 10 repetitions over
all drugs. MSEcv is the average of the mean squared error of 5-fold cross-validation
based on the 80% training cell lines, and MSEval is the average of the 10 repetitions
of predicted mean squared error based on the 20% testing cell lines. The range of R2val
is (−∞, 1]. The s.e. is the standard derivation over the 10 repetitions.
models as shown in Table 2. By taking into account the hierarchical group relationship of
97 drugs (in tree-lasso and IPF-tree-lasso) and the heterogeneity of different data sources
(in IPF-type methods), prediction performance can be improved further. IPF-tree-lasso
performs best, with MSEval=3.025 and R
2
val = 0.089 averaged over the 10 repetitions.
Nevertheless, as can be seen from R2val, all methods explain only a limited proportion of
variation in the drug sensitivity data across all drugs. When looking at the drug-specific
explained variation R2val and MSEval, the results differ widely between drugs.
For example, the IPF-tree-lasso model can explain 44.8% of the variation between cell
lines in their sensitivity to Nutlin-3α (Figure 6(a)). Nutlin-3α has been reported to be
effective in cancers across a wide range of tissue types due to its general mechanism of
action, which involves the p53-pathway that is affected in up to 50% of cancers in nearly
all cancer types (e.g. Olivier et al., 2002; Luo et al., 2013; Trino et al., 2016; Drakos et al.,
2011; Hui et al., 2018). Nutlin-3α therefore reaches a relatively large proportion of cancers,
which in addition can be characterized well by their molecular profiling, in particular by
their TP53 status and MDM2 expression. Consequently, improving the estimates for these
molecular features, e.g. by borrowing information across related p53-targeting drugs as can
be achieved by tree-lasso and IPF-tree-lasso, is particularly helpful for improving overall
prediction performance of Nutlin-3α. When we further split the prediction performance of
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Fig 6: R2val and MSEval for individual drugs by each method. The results are the average of
10 repetitions and based on the final models of each repetition. The top-right of (b) shows
the full y-axis with all drugs.
IPF-tree-lasso for Nutlin-3α by calculating the R2val separately for each cancer tissue type
(Table S7.1 of Supplementary S7), we observe high explained variation (R2val > 0.180) in
the digestive system, urogenital system, blood, kidney, nervous system, skin, soft tissue,
aerodigestive tract, lung, pancreas and bone tissue.
In addition to Nutlin-3α, drugs RDEA-119, 17-AAG, PD-0325901, CI-1040 and AZD6244
also reach much higher R2val for tree-lasso and IPF-tree-lasso than for the other methods
(Figure 6(a)). This indicates that these drugs benefit particularly well from the borrowing
of information across related drugs. In fact, drugs RDEA-119, PD-0325901, CI-1040 and
AZD6244 are all MEK inhibitors. These drugs with the same target have highly correlated
drug sensitivities and are clustered together in the hierarchical clustering used to deter-
mine the tree structure for tree-lasso and IPF-tree-lasso (Figure S7.1 of Supplementary
S7). Although the drug 17-AAG is a Hsp90 inhibitor, Calabrese et al. (2003) showed that
down-regulation of MEK1 activity markedly reduces the sensitivity of medulloblastoma,
breast, and ovarian cancer cells to 17-AAG; therefore 17-AAG can also benefit from the
borrowing of information in the tree-lasso methods, since it clusters quite closely together
with the above-mentioned MEK inhibitors.
As for the drug Methotrexate, all prediction models except the “NULL” model per-
form similarly well. Methotrexate is a cytotoxic chemotherapeutic drug which blocks the
enzyme dihydrofolate reductase which in turn results in cell death (Goodsell, 1999). It is
a very general mechanism of action and not targeted to specific genes or pathways, so
consequently the omics characterisation of the cell lines does not contribute further to the
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prediction performance for this drug. Even when only considering the tissue types with-
out genomic information, the “OLS” model for Methotrexate already reaches very good
prediction performance (R2val = 0.360).
Note, that for a few drugs, tree-lasso and IPF-tree-lasso do not perform well. In partic-
ular, the cell lines’ sensitivity to Nilotinib is on average predicted relatively well by lasso,
elastic-net, IPF-lasso and sIPF-elastic-net (R2val > 0.170), but cannot be predicted by tree-
lasso and IPF-tree-lasso (Figure 6(a)) where R2val < 0.002. When comparing the prediction
performance of Nilotinib for individual cancer tissue types, we have found that only blood
cell lines have much smaller MSEval for lasso, elastic-net, IPF-lasso and sIPF-elastic-net
compared to the tree-lasso-type methods. This may be because the mode of action of Nilo-
tinib is specific to chronic myeloid leukemia (a blood cancer), where it blocks a tyrosine
kinase protein coded by the fusion gene BCR-ABL which is found in most patients with
chronic myeloid leukemia (Blay and Von Mehren, 2011). Therefore, the presence of the
BCR-ABL fusion gene is a strong predictor for sensitivity to Nilotinib in blood cancer cell
lines. In fact, while there are only three blood cancer cell lines with BCR-ABL mutation
in this data set, all three show a very good sensitivity to Nilotinib with extremely low IC50
values (Figure S7.2 of Supplementary S7).
All lasso-type methods select the gene BCR-ABL for Nilotinib for all repetitions and
achieve good prediction for the three BCR-ABL mutated blood cell lines. But tree-lasso
neither selects the BCR-ABL mutation variable nor predicts drug sensitivity of the blood
cell lines well for Nilotinib, and although it is selected for Nilotinib by IPF-tree-lasso, the
absolute value of its coefficient estimate is very small. This is because the IC50’s of drugs
Nilotinib and Axitinib have strong correlation (Pearson correlation coefficient 0.57, Figure
S7.3 of Supplementary S7), and therefore the tree-lasso penalties shrink the coefficients
corresponding to these two drugs together which results in more similar predictions. While
the three BCR-ABL-mutated blood cell lines also show strong sensitivity to Axitinib, the
corresponding IC50 are not as extreme as for Nilotinib, so that the shrinkage of the regres-
sion coefficients of Nilotinib and Axitinib towards each other results in a worse prediction
for Nilotinib for these three extreme cell lines. This is reflected in the overall R2val, which
is strongly influenced by these three extreme data points.
Other drugs including Bicalutamide, LFM-A13, SL-0101-1, CCT007093, NSC-87877 and
ABT-888 show small R2val values (R
2
val < 0.050) for all methods (Figure 6(a)). All these
drugs have very small MSEval values, even for the NULL model (Figure 6(b)), which
indicates low heterogeneity in the log IC50 values for these drugs. In short, there is not
much variability between cell lines that could be explained by the molecular data or tissue
type information available.
In Table 2, V S? =
∑p
j=1
∑m
k=1
{(∑10
r=1 1{βˆ(r)jk 6=0}
)
≥ 2
}
indicates the number of fea-
tures selected at least twice over the ten repetitions1. We note that lasso, elastic net and
IPF-lasso perform very sparse variable selection with fewer than 860 out of p×m = 300312
features estimated to be nonzero more than once over ten repetitions, which corresponds to
0.3% of all features. Although sIPF-elastic-net has slightly better average prediction perfor-
1Accordingly, throughout this paragraph we refer to a feature as being selected, if it has an estimated
non-zero regression coefficient in at least two out of ten repetitions.
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mance than standard lasso and elastic net, it results in an almost dense coefficient matrix
with α = 0.39 (where α is the averaged optimal value over the 10 repetitions) compared to
the elastic net with α = 0.77. Both tree-lasso-type methods are sparser than sIPF-elastic-
net with V S? = 30078 for tree-lasso and V S? = 31534 for IPF-tree-lasso (corresponding to
10.0% and 10.5% of all features, respectively). Tree-lasso selects many more copy number
features than IPF-tree-lasso, but only one mutation feature: TP53 for drug Nutlin-3α. In
contrast, IPF-tree-lasso selects 537 associated mutated gene features. In particular, the
following drugs with R2val > 0.100 select the following mutation features corresponding to
the drugs’ respective targets: B-Raf for drugs PLX4720 and SB590885, EGFR/ErbB for
drug BIBW2992 (Afatinib), BCR-ABL for Nilotinib and TP53 for Nutlin-3α. In addition,
drugs RDEA119, 17-AAG, PD-0325901, CI-1040 and AZD6244 all select genes in their
target Ras/Raf/MEK/ERK signalling pathway by IPF-tree-lasso. All target genes selected
by different methods for drugs with R2val > 0.100 are shown in Table S7.2 of Supplementary
S7.
5. Conclusion. In this study, we used multi-omics data to jointly predict sensitivity
of cancer cell lines to multiple cancer drugs. It was our goal that the penalized regression
should take into account both, the heterogeneity in the multi-omics data as well as (hier-
archical) relationships between drugs. We extended the tree-lasso to IPF-tree-lasso, which
can achieve the two purposes simultaneously. The implementation of IPF-tree-lasso is made
feasible by weighting the data by the penalty parameters. Question: What is meant by the
previous sentence? In addition, based on IPF-lasso (Boulesteix et al., 2017), we formulated
the IPF-elastic-net, which is an option to tune the varying penalty parameters λs and αs
in (2.3) separately for each data source s ∈ [S], thus allowing differing degrees of both,
sparsity and grouping effect, in the different data sources. If one has prior knowledge on
the sparsity of the different data sources, IPF-elastic-net can specify the penalty terms for
some data sources as lasso penalties for instance, i.e. specify those αs values as 1. Finally,
we provide a unified framework for the transformation of a large class of general IPF-type
penalized problems into the equivalent original penalized problems in proposition 1. Fur-
thermore, we demonstrated how the interval-search algorithm EPSGO (Frohlich and Zell,
2005) can be used to optimize multiple penalty parameters efficiently.
To capture the heterogeneity of different features, Bergersen, Glad and Lyng (2011)
proposed the weighted lasso to use external information to generate penalty weights, e.g.
to use external copy number data to provide weights for gene expression features. Van de
Wiel et al. (2016) developed adaptive group-regularized ridge regression (“GRridge”) to use
related co-data (e.g. annotation or external p values) to derive group-specific penalties by
empirical Bayes estimation; only one global penalty parameter needs to be optimized, e.g.
by cross-validation. These methods use other data as auxiliary information to determine
(group) weights in the penalty term. Contrary to these approaches, in IPF-type methods
all data contribute to the outcomes directly. Dondelinger and Mukherjee (2018) proposed
joint lasso to penalize subgroup-specific (i.e., cancer tissue) coefficients differently with an
additional fusion penalty term, but they used the same penalty parameter value for all
high-dimensional features. Klau et al. (2018) presented priority-lasso to construct blocks
of multi-omics data sources and regress on each data source sequentially, but this provides
only limited interpretation of the resulting variable selection. Wu et al. (2019) selectively
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reviewed multi-level omics data integration methods, but focused on univariate outcomes.
In our analysis of the GDSC data set, the overall low R2val highlights the limitations in
using only tissue type and genomic information to predict drug sensitivity. Wang et al.
(2017) and Ali et al. (2018) showed that proteomes of human cancer cell lines are more
representative of primary tumors than genomic profiles alone and might thus improve the
prediction of drug sensitivity. Chambliss and Chan (2016) and others recommended to
integrate pharmacoproteomics and pharmacogenomics profiles of the tumor samples to
help identify the right therapeutic regimen.
One disadvantage of IPF-type methods is that they cannot address known associations
between features in the different data sources, e.g., between gene expression and muta-
tion status of the same gene. However, the sIPF-elastic-net employs a common α for all
data sources, which is likely to select the strongly correlated features over all data sources
together if α is small. As for IPF-tree-lasso, specifying similar weights for coefficients of
associated internal nodes in (2.5) across different data sources may select correlated fea-
tures over multiple data sources. Furthermore, the inclusion of biological pathways of genes
related to the cancer may improve the biological interpretation and prediction of drug sen-
sitivity as well. Li and Li (2008) and Lee et al. (2016) proposed pathway-based approaches
to identify biologically relevant pathways related to interesting phenotype. The tree-lasso
or IPF-tree-lasso can also be extended to include the pathway-group structure over features
in the penalty term besides the hierarchical structure over response variables.
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